Patents by Inventor Franklin Porter Bymaster

Franklin Porter Bymaster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS
    Publication number: 20210046044
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.
    Type: Application
    Filed: May 4, 2020
    Publication date: February 18, 2021
    Inventors: Anthony Alexander McKinney, Franklin Porter Bymaster
  • USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS
    Publication number: 20180296527
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.
    Type: Application
    Filed: November 15, 2017
    Publication date: October 18, 2018
    Inventors: Anthony Alexander McKinney, Franklin Porter Bymaster
  • USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS
    Publication number: 20170216251
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.
    Type: Application
    Filed: September 6, 2016
    Publication date: August 3, 2017
    Inventors: Anthony Alexander McKinney, Franklin Porter Bymaster
  • USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS
    Publication number: 20140315892
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.
    Type: Application
    Filed: January 31, 2014
    Publication date: October 23, 2014
    Inventors: Anthony Alexander McKinney, Franklin Porter Bymaster
  • Combination therapy for treatment of psychoses
    Publication number: 20040023951
    Abstract: The invention provides combination therapy comprising a first component which is a typical antipsychotic or an atypical antipsychotic and a second component which is a muscarinic agonist for the treatment of psychoses and other disorders.
    Type: Application
    Filed: November 25, 2002
    Publication date: February 5, 2004
    Inventors: Franklin Porter Bymaster, Harlan Edgar Shannon
  • Transdermal formulation of xanomeline
    Patent number: 5980933
    Abstract: The present invention provides a method for treating Alzheimer's Disease using a xanomeline transdermal formulation. The invention provides desired transdermal xanomeline patch formulations.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Liily and Company
    Inventors: Franklin Porter Bymaster, Michael Horstmann, Harlan E. Shannon, Lisa A. Shipley, Kirti H. Valia
  • Antipsychotic method
    Patent number: 5968926
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 19, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben Olesen, John Stanley Ward, Charles H. Mitch
  • Transdermal formulation
    Patent number: 5858393
    Abstract: The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-?4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo-?2.2.2!octane transdermal formulation. The invention provides desired transdermal 3-?4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo?2.2.2!octane patch formulations.
    Type: Grant
    Filed: August 25, 1997
    Date of Patent: January 12, 1999
    Assignee: Eli Lilly and Company
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Lisa A. Shipley, Kirti H. Valia
  • Antipsychotic method
    Patent number: 5753683
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: January 29, 1996
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon
  • Method of treating schizophrenia
    Patent number: 5750541
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases by administering thiadiazole or oxadiazole compounds.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: May 12, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon
  • Antipsychotic method
    Patent number: 5679686
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 21, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
  • Antipsychotic method
    Patent number: 5677313
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 14, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
  • Antipsychotic method
    Patent number: 5663182
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: September 2, 1997
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch